Tayla Poretta, Pharm D, Mph
About Tayla Poretta, Pharm D, Mph
Tayla Poretta, Pharm.D., MPH, is the Associate Director of Health Economics and Outcomes Research (HEOR) for the US Market in Oncology at Bristol Myers Squibb.
Current Position at Bristol Myers Squibb
Tayla Poretta serves as the Associate Director of Health Economics and Outcomes Research (HEOR) for the US Market, focusing on oncology at Bristol Myers Squibb. Based in the New York City Metropolitan Area, she is actively involved in developing health economic models to support reimbursement strategies for oncology drugs and integrating health economics data into clinical development plans.
Previous Roles at Bristol Myers Squibb
Prior to her current role, Tayla Poretta held multiple positions at Bristol Myers Squibb. From 2020 to 2021, she served as Senior Manager in the same field and market segment. Before that, she was a Post-Doctoral Fellow working on cardiovascular and immunology health economics and outcomes research from 2018 to 2020.
Academic Background and Teaching Experience
Tayla Poretta holds a Doctor of Pharmacy (Pharm.D.) and a Bachelor of Pharmacy (BPharm) from Northeastern University, as well as a Master of Public Health (MPH) in Epidemiology from the Rutgers School of Public Health. She also served as an Adjunct Faculty member at Rutgers University–New Brunswick from 2018 to 2020, where she mentored pharmacy students.
Internships and Early Career Experience
Tayla has accumulated diverse experience through various internship roles. She interned at prestigious institutions such as McLean Hospital, Brigham and Women's Hospital, FDA, BGB Group, Industry Pharmacists Organization, CVS Health, and Dana-Farber Cancer Institute. These roles ranged from pharmacy intern positions to drug information and regulatory internships, providing her a well-rounded foundation in health economics and pharmacy practice.
Research Contributions and Presentations
Tayla Poretta has contributed to several peer-reviewed publications in the field of oncology health economics. She has presented her research findings at major national conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting. Her work involves participating in cross-functional teams to incorporate health economic data into clinical development plans and supporting oncology drug reimbursement strategies.